At the Wells Fargo 21st Annual Healthcare Conference on Sept. 8, 2026, argenx CEO Karen Massey detailed the company’s strategy to broaden its immunology franchise beyond the FcRn inhibitor VYVGART (efgartigimod). The firm reported second‑quarter revenue of $1.5 billion and highlighted a strong balance sheet, with a current ratio of 5.12 and a return on assets of 19.93%.
Massey outlined argenx’s "Vision 2030" goal to treat 50,000 patients across ten indications with five new late‑stage molecules by the end of the decade. The addressable market for myasthenia gravis (MG) was revised upward to 60,000 patients, split into 25,000 early‑line, 7,000 ocular, 11,000 seronegative and 17,000 refractory cases. She noted that 80% of MG patients remain untreated with a targeted biologic and that four out of five neurologists consider VYVGART their first‑line choice.
The pipeline updates included a Phase III myositis trial (IMNM and dermatomyositis) that demonstrated a 15‑point advantage on the Tissue Involvement Scale with statistical significance. Empasiprubart, a second FcRn inhibitor, entered Phase III for motor neuron disease with a non‑inferiority primary endpoint to IVIG and is also being evaluated in CIDP and graft‑versus‑host disease. A subcutaneous formulation is in Phase I.
argenx also discussed its recent acquisition of Forte Biosciences. The FB102 CD122 inhibitor, de‑risked by positive Phase II vitiligo data, is now being studied in vitiligo, alopecia areata and celiac disease, with a Phase II learning study in celiac patients underway.
Future product plans feature an extended‑half‑life FcRn inhibitor ready for Phase III, an oral FcRn candidate described as a potential "game changer," and an autoinjector for VYVGART slated for launch next year. The company marked 18 quarters since VYVGART’s market entry and cited 20,000 patient‑years of safety data.
Massey emphasized that while VYVGART provides a solid foundation, argenx’s broader immunology ambition requires additional molecules to meet unmet needs across multiple rare diseases.
